^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NR4A3 rearrangement + KIT mutation

    i
    Other names: Nuclear receptor subfamily 4 group A member 3, Mitogen-induced nuclear orphan receptor, Neuron-derived orphan receptor, Nuclear hormone receptor NOR-1, KIT, KIT proto-oncogene receptor tyrosine kinase, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815; 8013
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3years
    Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation. (PubMed, BMJ Case Rep)
    The patient has been on imatinib, a tyrosine kinase inhibitor with activity against KIT, for 3 years with stable disease. Metastatic EMC is generally treated with surgical resection and perioperative radiation therapy with adjuvant chemotherapy and is associated with poor prognosis.
    Clinical • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • NR4A3 (Nuclear receptor subfamily 4 group A member 3)
    |
    KIT mutation • KIT exon 11 mutation • NR4A3 rearrangement + KIT mutation
    |
    imatinib